市場調査レポート
商品コード
1439212
臨床化学分析装置市場:製品タイプ別、検査タイプ別、エンドユーザー別、地域別、機会、予測、2017年~2031年Clinical Chemistry Analyzers Market Assessment, By Product, By Test Type, By End-user, By Region, Opportunities and Forecast, 2017-2031F |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
臨床化学分析装置市場:製品タイプ別、検査タイプ別、エンドユーザー別、地域別、機会、予測、2017年~2031年 |
出版日: 2024年02月28日
発行: Market Xcel - Markets and Data
ページ情報: 英文 225 Pages
納期: 3~5営業日
|
世界の臨床化学分析装置の市場規模は、2024年~2031年の予測期間中に4.67%のCAGRで拡大し、2023年の152億3,000万米ドルから2031年には219億4,000万米ドルに成長すると予測されています。高齢者人口の増加、慢性疾患の有病率の上昇、ポイントオブケア検査の重要性と認知度の上昇、技術の進歩、診断検査室における分析装置の使用の増加、検査室の自動化などの要因です。
人口動態の変化、ヘルスケア動向、技術進歩など様々な要因が世界の臨床化学分析装置市場に影響を与えています。世界人口の高齢化は世界の臨床化学分析装置市場の重要な促進要因であり、高齢者はより頻繁な健康監視を必要とするため、臨床化学検査の需要が増加します。さらに、糖尿病、心臓病、がんなど、継続的なモニタリングと検査が必要な慢性疾患の蔓延が需要を押し上げています。
ポイントオブケア検査は、その利便性と迅速な結果によって、世界の臨床化学分析装置市場でますます重要性を増しています。その結果、外来診療所や在宅医療の現場など、従来の検査室以外での使用に適したコンパクトで使いやすい臨床化学分析装置の需要が高まっています。これらの分析装置はタイムリーな臨床判断を可能にし、さまざまな医療現場で不可欠なツールとなっています。
技術の進歩は世界の臨床化学分析装置市場の形成に重要な役割を果たしています。自動化の導入と検査情報システムとの統合により、分析装置の技術は効率と精度を向上させ、感度と特異度を向上させながら幅広い検査を実施できるようになっています。このような技術の進歩は、検査室の自動化が進み、大量の検査を迅速に処理する必要性と相まって、患者ケアを向上させ、世界の臨床化学分析装置市場の成長を牽引してきました。その結果、臨床化学分析装置は現代のヘルスケア診断に不可欠な要素となっています。
世界の臨床化学分析装置市場は、ポイントオブケア(POC)検査に対する意識の高まりによって牽引されています。POC検査では、診療所や患者の自宅など、患者の診療現場で直接、迅速な診断結果を得ることができます。これは、急性疾患の管理、慢性疾患のモニタリング、あるいは定期的な健康診断の効率的な実施に極めて重要です。患者やヘルスケア・プロバイダーがPOC検査の利便性、迅速性、より良い健康結果の可能性などの利点を認識するにつれ、従来の検査室環境以外で正確な結果を提供できる臨床化学分析装置に対する需要が急増しています。この動向は技術の進歩を促し、世界の臨床化学分析装置市場を拡大しています。メーカー各社は需要の増加に対応するため、よりコンパクトで使いやすく、汎用性の高い分析装置を開発しています。
当レポートでは、世界の臨床化学分析装置市場について調査し、市場の概要とともに、製品タイプ別、検査タイプ別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。
Global clinical chemistry analyzers market is projected to witness a CAGR of 4.67% during the forecast period 2024-2031, growing from USD 15.23 billion in 2023 to USD 21.94 billion in 2031. Factors such as increasing elderly population, growing prevalence of chronic diseases, rising importance and awareness of point-of-care testing, technological advancements, increasing use of analyzers in diagnostic laboratories, and automation of laboratories.
Various factors, including demographic changes, healthcare trends, and technological advancements influence the global clinical chemistry analyzers market. The aging global population is a significant driver of the global clinical chemistry analyzers market, as older individuals need more frequent health monitoring, which increases the demand for clinical chemistry testing. The demand is further fueled by the growing prevalence of chronic diseases like diabetes, heart disease, and cancer, which require continuous monitoring and testing.
Point-of-care testing have become increasingly important in the global clinical chemistry analyzers market due to its convenience and fast results. It has resulted in a higher demand for compact and user-friendly clinical chemistry analyzers suitable for use outside of traditional labs, such as outpatient clinics and home care settings. These analyzers enable timely clinical decisions, making them an essential tool in various medical settings.
Technological advancements have played a crucial role in shaping the global clinical chemistry analyzers market. With the introduction of automation and integration with lab information systems, analyzer technology has improved efficiency, accuracy, and the ability to perform a wider range of tests with improved sensitivity and specificity. The technological progression, coupled with the increasing automation of laboratories to handle high test volumes and the need for quick turnaround times, has improved patient care and driven the growth of the global clinical chemistry analyzers market. As a result, they have become an essential component of modern healthcare diagnostics.
In May 2023, Roche Diagnostics exhibited their lab automation technologies, serum work area solutions, and molecular and point-of-care solutions at WorldLab-EuroMedLab 2023 in Rome. One of the products displayed was the Navify portfolio, which consists of integrated digital solutions that facilitate open digital ecosystems. These solutions connect to innovations, improve operational efficiencies, and provide actionable insights to improve patient care.
Awareness of Point-Of-Care Testing
The global clinical chemistry analyzers market is being driven by the increasing awareness of point-of-care (POC) testing. POC testing enables rapid diagnostic results to be obtained directly at the site of patient care, such as clinics or patient homes. It facilitates immediate clinical decision-making and treatment initiation, which is crucial for managing acute conditions, monitoring chronic diseases, or conducting routine health checks efficiently. As patients and healthcare providers recognize the benefits of POC testing, such as convenience, speed, and potential for better health outcomes, the demand for clinical chemistry analyzers capable of delivering accurate results outside traditional laboratory settings has surged. The trend is pushing advancements in technology and expanding the global clinical chemistry analyzers market, as manufacturers develop more compact, user-friendly, and versatile analyzers to meet the growing demand.
In July 2023, B&E Biotechnology Co. Ltd. launched a new product called the i-Check handheld blood gas electrolyte analyzer. The high-tech device is designed to help with clinical diagnostic applications and uses microfluidic and electrochemical detection technology.
Advancements in Technology
Technological advancements are playing a crucial role in driving the growth of global clinical chemistry analyzers market forward by introducing innovation and improving efficiency. These analyzers are becoming more advanced, offering improved accuracy, speed, and the ability to perform a wider range of tests. With the help of automation, manual labor is reduced, and errors are minimized, which enhances laboratory productivity and reduces turnaround times for results. Integration with laboratory information systems (LIS) creates seamless data management and sharing, improving workflow, and patient care. Additionally, the development of compact, user-friendly designs is enabling the expansion of point-of-care testing, making clinical chemistry analyzers more accessible and versatile. These technological improvements meet the growing demands of healthcare providers and contribute to the overall growth of the global clinical chemistry analyzers market by enabling more efficient, accurate, and comprehensive diagnostic testing.
In May 2023, Goldsite Diagnostics Inc., a leading Chinese diagnostics manufacturer, launched FIA Go. It is a compact fluorescent immunoassay analyzer that is specifically designed for POCT (point-of-care testing) settings. The instrument is based on TRFIA (time-resolved fluorescence immunoassay) technology, which ensures high precision and low interference. FIA Go is a high-performance portable analyzer that comes with a wide-ranging parameter menu. It provides professionals with high-quality medical information and user-friendly handling.
Increasing Use of Analyzers in Diagnostic Laboratories
The increasing use of clinical chemistry analyzers in diagnostic laboratories is a pivotal factor propelling the global clinical chemistry analyzers market. These analyzers are essential for diagnosing and monitoring a wide array of health conditions, from routine biochemical profiles to complex disease markers. As the volume of patients seeking diagnostic services grows, due to rising awareness of health issues and the prevalence of chronic diseases, laboratories are under pressure to deliver accurate and timely results. Clinical chemistry analyzers, with their ability to automate and streamline testing processes, are indispensable in meeting the demand. Their efficiency in handling large test volumes, accuracy in results, and versatility in testing capabilities make them critical to the operational success of diagnostic laboratories, driving the growth of the global clinical chemistry analyzers market.
For instance, in July 2023, Siemens Healthineers announced the launch of Atellica CI Analyzer for clinical chemistry and immunoassay testing. Atellica CI Analyzer enables both standalone labs and satellite labs within larger health networks to access the same reagents, consumables, and intelligent software found in the company's Atellica Solution.
Increasing Demand of Analyzers
The global clinical chemistry analyzers market is growing rapidly due to the increasing demand for these devices in healthcare settings. The growth is driven by the rising global population and the corresponding increase in the prevalence of chronic illnesses such as diabetes, cardiovascular disorders, and cancer, which require continuous monitoring and testing. Moreover, the healthcare industry's shift towards preventive care and personalized medicine emphasizes regular health screenings, leading to higher demand for clinical chemistry analyzers. These devices provide quick and accurate testing of various biomarkers, enabling early detection and management of diseases, which in turn improves patient outcomes and boosts the global clinical chemistry analyzers market.
In July 2023, Beckman Coulter Diagnostics, a clinical diagnostics leader, received FDA clearance for its new DxC 500 AU Chemistry Analyzer. It is an automated chemistry analyzer which expands the company's clinical chemistry offering and demonstrates their ongoing commitment to product innovation in the in-vitro diagnostic industry. The DxC 500 AU Chemistry Analyzer is designed for small-to-medium-sized laboratories and is one of several recent solutions provided by Beckman Coulter that are designed to optimize laboratory workflows and support critical clinical decisions.
North America Dominates the Market
North America is currently at the forefront of the global clinical chemistry analyzers market. This is due to several key factors. The region boasts a robust healthcare infrastructure with a significant emphasis on research and development, which fosters innovation in diagnostic technologies, including clinical chemistry analyzers. Furthermore, the high prevalence of chronic diseases, such as diabetes and cardiovascular conditions, in North America requires widespread diagnostic testing, thereby increasing the demand for analyzers. Additionally, the region's strong focus on preventive healthcare and early disease detection, coupled with the availability of healthcare funding and insurance coverage, facilitates greater access to diagnostic testing services. These dynamics collectively contribute to North America's dominance in the global clinical chemistry analyzers market, driving advancements and adoption of these critical diagnostic tools.
In July 2023, Beckman Coulter, a leader in clinical diagnostics, unveiled the DxI 9000 Access Immunoassay Analyzer in North America for the first time. The analyzer has been designed to meet the demands of clinical laboratories for speed, reliability, reproducibility, quality, and menu expansion. It has the ability to develop increasingly sensitive and clinically relevant assays, enabling the platform to keep pace with tomorrow's testing requirements as healthcare providers and pharmaceutical companies tackle challenging diseases.
Future Market Scenario (2024 - 2031F)
The global clinical chemistry analyzers market is expected to be significantly impacted by the integration of AI and ML technologies. These advancements will enhance the analyzers' ability to interpret complex test results more accurately and efficiently, which will enable personalized patient care through predictive analytics.
The demand for point-of-care testing is expected to increase due to the need for rapid diagnostic results in decentralized healthcare settings.
Automation in clinical chemistry analyzers will significantly boost the growth of the global clinical chemistry analyzers market by improving efficiency, reducing human error, and increasing throughput in laboratories, thereby meeting the rising demand for fast and accurate diagnostic testing.
As healthcare systems transition to preventive care for better population health and cost management, regular health screenings will become more prevalent.
Key Players Landscape and Outlook
The global clinical chemistry analyzers market is being driven by strategic partnerships between major healthcare companies. These collaborations are essential for combining resources, expertise, and technologies to innovate and improve diagnostic solutions. By working together, companies can accelerate the development and distribution of advanced clinical chemistry analyzers, offering better functionality, accuracy, and efficiency. Such partnerships often focus on expanding product portfolios, entering new markets, and enhancing the customer base. Additionally, these collaborations can lead to the integration of complementary technologies, such as combining analyzers with digital platforms for data analysis, thereby creating more value for healthcare providers. All these factors contribute significantly to the growth of the global clinical chemistry analyzers market.
In June 2022, Beckman Coulter, a global leader in clinical diagnostics, announced a new partnership with Smart4Diagnostics, a Germany-based company. The partnership aims to close the preanalytical data gap between blood collection and laboratory analysis by addressing errors that occur before the sample reaches the laboratory. These errors may include sample collection, patient identification, sample handling, sample transportation, and sample loss.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.